Skip header and navigation

3 records – page 1 of 1.

Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.

https://arctichealth.org/en/permalink/ahliterature133553
Source
BMC Infect Dis. 2011;11:177
Publication Type
Article
Date
2011
Author
Nanna Hansen
Niels Obel
Peer B Christensen
Mette Kjær
Alex L Laursen
Henrik B Krarup
Axel Møller
Poul Schlichting
Jens Bukh
Nina Weis
Author Affiliation
Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, 2650 Hvidovre, Denmark.
Source
BMC Infect Dis. 2011;11:177
Date
2011
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antiviral Agents - administration & dosage
Cohort Studies
Denmark - epidemiology
Female
Hepacivirus - genetics - isolation & purification
Hepatitis C, Chronic - drug therapy - epidemiology - virology
Humans
Interferon-alpha - administration & dosage
Logistic Models
Male
Middle Aged
Polyethylene Glycols - administration & dosage
RNA, Viral - blood
Recombinant Proteins
Ribavirin - administration & dosage
Treatment Outcome
Abstract
The effect of peginterferon and ribavirin treatment on chronic hepatitis C virus (HCV) infection has been established in several controlled clinical studies. However, the effectiveness of treatment and predictors of treatment success in routine clinical practice remains to be established. Our aim was to estimate the effectiveness of peginterferon and ribavirin treatment in unselected HCV patients handled in routine clinical practice. The endpoint was sustained virological response (SVR), determined by the absence of HCV RNA 24 weeks after the end of treatment.
We determined the proportion of SVR in a nationwide, population-based cohort of 432 patients with chronic HCV infection who were starting treatment, and analyzed the impact of known covariates on SVR by using a logistic regression analysis.
The majority of treated patients had genotype 1 (133 patients) and genotype 2/3 (285 patients) infections, with 44% and 72%, respectively, obtaining SVR. Other than genotype, the predictors of SVR were age=45 years at the start of treatment, completion of unmodified treatment, the absence of cirrhosis and non-European origin.
The effectiveness of peginterferon and ribavirin treatment for chronic hepatitis C in a routine clinical practice is comparable to that observed in controlled clinical trials, with a higher SVR rate in genotype 2 and 3 patients compared to genotype 1 patients. Our data further indicate that age at start of treatment is a strong predictor of SVR irrespective of HCV genotype, with patients 45 years or younger having a higher SVR rate.
Notes
Cites: N Engl J Med. 2007 Jul 12;357(2):124-3417625124
Cites: Nat Rev Gastroenterol Hepatol. 2011 May;8(5):257-6421468124
Cites: Hepatology. 2008 Jan;47(1):35-4217975791
Cites: Hepatology. 2008 May;47(5):1453-6118435468
Cites: Eur J Intern Med. 2008 Jun;19(4):266-7018471675
Cites: Hepatology. 2008 Jun;47(6):1837-4518454508
Cites: Hepatology. 2008 Aug;48(2):69518666232
Cites: J Hepatol. 2008 Oct;49(4):634-5118715665
Cites: Hepatology. 2008 Dec;48(6):1753-6018925643
Cites: J Viral Hepat. 2009 Sep;16(9):659-6519486467
Cites: Nature. 2009 Sep 17;461(7262):399-40119684573
Cites: J Viral Hepat. 2000 Nov;7(6):435-911115055
Cites: Lancet. 2001 Sep 22;358(9286):958-6511583749
Cites: N Engl J Med. 2002 Sep 26;347(13):975-8212324553
Cites: Hepatology. 2002 Nov;36(5 Suppl 1):S47-5612407576
Cites: J Clin Microbiol. 2003 Mar;41(3):1091-10012624035
Cites: Scand J Infect Dis. 2003;35(8):445-5114514142
Cites: Ann Intern Med. 2004 Mar 2;140(5):346-5514996676
Cites: Nat Genet. 2009 Oct;41(10):1105-919749757
Cites: Nat Genet. 2009 Oct;41(10):1100-419749758
Cites: Hepatology. 2004 Apr;39(4):1147-7115057920
Cites: Hepatology. 1996 Jun;23(6):1334-408675148
Cites: Hepatology. 1996 Aug;24(2):289-938690394
Cites: Scand J Clin Lab Invest. 1998 Aug;58(5):415-229819190
Cites: N Engl J Med. 2005 Jun 23;352(25):2609-1715972867
Cites: J Clin Microbiol. 2005 Aug;43(8):3877-8316081925
Cites: J Hepatol. 2006 Jan;44(1):97-10316290907
Cites: Scand J Gastroenterol. 2007 Feb;42(2):247-5517327945
Cites: Hepatology. 2007 Mar;45(3):806-1617326207
Cites: Am J Gastroenterol. 2007 Jul;102(7):1383-9117403072
Cites: Hepatology. 2007 Jul;46(1):37-4717567830
Cites: Gastroenterology. 2010 Sep;139(3):821-7, 827.e120621700
Cites: Am J Gastroenterol. 2007 Oct;102(10):2181-817640318
PubMed ID
21693019 View in PubMed
Less detail

Environmental pollutants in blood donors: The multicentre Norwegian donor study.

https://arctichealth.org/en/permalink/ahliterature307350
Source
Transfus Med. 2020 Jun; 30(3):201-209
Publication Type
Journal Article
Date
Jun-2020
Author
Maria Averina
Tor Hervig
Sandra Huber
Mette Kjaer
Einar K Kristoffersen
Bjørn Bolann
Author Affiliation
Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway.
Source
Transfus Med. 2020 Jun; 30(3):201-209
Date
Jun-2020
Language
English
Publication Type
Journal Article
Abstract
The aim of this study was to measure blood concentrations of environmental pollutants in Norwegian donors and evaluate the risk of pollutant exposure through blood transfusions.
Transfused blood may be a potential source of exposure to heavy metals and organic pollutants and presents a risk to vulnerable patient groups such as premature infants.
Donors were randomly recruited from three Norwegian blood banks: in Bergen, Tromsø and Kirkenes. Selected heavy metals were measured in whole blood using inductively coupled plasma mass spectrometry (ICP-MS), and perfluoroalkyl substances (PFAS) were measured in serum by ultrahigh-pressure liquid chromatography coupled with a triple-quadrupole mass spectrometer (UHPLC-MS/MS).
Almost 18% of blood donors had lead concentrations over the limit suggested for transfusions in premature infants (0.09?µmol/L). About 11% of all donors had mercury concentrations over the suggested limit of 23.7 nmol/L. Cadmium was higher than the limit, 16?nmol/L, in 4% of donors. Perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations were over the suggested limit of 0.91?ng/mL in 68% and 100% of the donors, respectively. PFAS concentrations and heavy metal concentrations increased with donor's age.
A considerable percentage of donors had lead, PFOS and PFOA concentrations over the suggested limits. In addition, at each study site, there were donors with high mercury and cadmium concentrations. Selecting young donors for transfusions or measurements of pollutants in donor blood may be a feasible approach to avoid exposure through blood transfusions to vulnerable groups of patients such as premature infants.
PubMed ID
31926037 View in PubMed
Less detail

Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.

https://arctichealth.org/en/permalink/ahliterature139287
Source
Eur J Gastroenterol Hepatol. 2011 Jan;23(1):41-4
Publication Type
Article
Date
Jan-2011
Author
Ellen Sloth Andersen
Belinda Klemmensen Moessner
Peer Brehm Christensen
Mette Kjær
Henrik Krarup
Søren Lillevang
Nina Weis
Author Affiliation
Departments of Infectious Diseases, Hvidovre, Copenhagen University Hospital, Rigshospitalet, Denmark. ellensloth@dadlnet.dk
Source
Eur J Gastroenterol Hepatol. 2011 Jan;23(1):41-4
Date
Jan-2011
Language
English
Publication Type
Article
Keywords
Alanine Transaminase - blood
Antiviral agents - therapeutic use
Cohort Studies
Denmark
Elasticity Imaging Techniques
Female
Hepacivirus - drug effects - isolation & purification
Hepatitis C, Chronic - drug therapy - pathology - ultrasonography
Humans
Hyaluronic Acid - blood
Interferon-alpha - therapeutic use
Liver - pathology - ultrasonography
Liver Cirrhosis - pathology - ultrasonography
Male
Middle Aged
Platelet Count
Polyethylene Glycols - therapeutic use
Recombinant Proteins
Ribavirin - therapeutic use
Treatment Outcome
Abstract
Transient elastography (TE) is a noninvasive and well validated method for measurement of liver stiffness. The aim of this study was to use TE to evaluate whether patients with sustained virological response (SVR) have lower liver stiffness than patients with non-SVR after treatment for chronic hepatitis C (CHC).
Patients with CHC, who had undergone liver biopsy before treatment with pegylated interferon and ribavirin, were included from four clinical centres in Denmark. All patients were examined with TE and had a blood test taken for hepatitis C virus-virus detection and analysis of alanine aminotransferase, platelet counts and hyaluronic acid.
For 110 (92%) of the 120 patients included, it was possible to obtain a successful measurement of liver stiffness. Of these, 71 (64.5%) had achieved SVR. Median follow-up time was 47 months. Patients with pretreatment minimal fibrosis (F0/F1) in their liver biopsy had median liver stiffness of 5.3 kPa for SVR versus 6.1 kPa for non-SVR (P=0.56). Patients with pretreatment moderate fibrosis (F2/F3) had median liver stiffness of 5.4 kPa for SVR versus 9.4 kPa for non-SVR (P
PubMed ID
21079513 View in PubMed
Less detail